nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—JAK1—Antiviral mechanism by IFN-stimulated genes—EIF4A3—vaginal cancer	0.0133	0.0403	CbGpPWpGaD
Ruxolitinib—JAK1—Regulation of IFNA signaling—IFNA1—vaginal cancer	0.0109	0.0333	CbGpPWpGaD
Ruxolitinib—PLK1—uterine cervix—vaginal cancer	0.00911	0.0136	CbGeAlD
Ruxolitinib—DYRK1A—T-Cell Receptor and Co-stimulatory Signaling—IL2—vaginal cancer	0.0088	0.0267	CbGpPWpGaD
Ruxolitinib—CAMK2G—Interferon Signaling—EIF4A3—vaginal cancer	0.00826	0.0251	CbGpPWpGaD
Ruxolitinib—TYK2—Regulation of IFNA signaling—IFNA1—vaginal cancer	0.00808	0.0246	CbGpPWpGaD
Ruxolitinib—PLK1—mammalian vulva—vaginal cancer	0.00797	0.0119	CbGeAlD
Ruxolitinib—PLK1—uterus—vaginal cancer	0.00759	0.0113	CbGeAlD
Ruxolitinib—PRKCE—Downstream signaling in naïve CD8+ T cells—IFNA1—vaginal cancer	0.00715	0.0218	CbGpPWpGaD
Ruxolitinib—CAMK1—uterine cervix—vaginal cancer	0.00711	0.0106	CbGeAlD
Ruxolitinib—PRKCE—female reproductive system—vaginal cancer	0.00711	0.0106	CbGeAlD
Ruxolitinib—PLK3—urethra—vaginal cancer	0.00699	0.0104	CbGeAlD
Ruxolitinib—PLK3—endometrium—vaginal cancer	0.00688	0.0102	CbGeAlD
Ruxolitinib—RPS6KA6—female reproductive system—vaginal cancer	0.00683	0.0102	CbGeAlD
Ruxolitinib—PLK1—female reproductive system—vaginal cancer	0.00683	0.0102	CbGeAlD
Ruxolitinib—PLK3—mammalian vulva—vaginal cancer	0.00665	0.00991	CbGeAlD
Ruxolitinib—JAK1—Interferon Signaling—EIF4A3—vaginal cancer	0.00655	0.0199	CbGpPWpGaD
Ruxolitinib—CAMK1—urethra—vaginal cancer	0.00654	0.00974	CbGeAlD
Ruxolitinib—CAMK1—endometrium—vaginal cancer	0.00643	0.00958	CbGeAlD
Ruxolitinib—CAMK1—mammalian vulva—vaginal cancer	0.00622	0.00927	CbGeAlD
Ruxolitinib—JAK1—epithelium—vaginal cancer	0.00588	0.00877	CbGeAlD
Ruxolitinib—TAOK2—urethra—vaginal cancer	0.00587	0.00875	CbGeAlD
Ruxolitinib—DCLK3—vagina—vaginal cancer	0.00585	0.00872	CbGeAlD
Ruxolitinib—JAK1—uterine cervix—vaginal cancer	0.00583	0.00869	CbGeAlD
Ruxolitinib—DCLK1—uterine cervix—vaginal cancer	0.00583	0.00869	CbGeAlD
Ruxolitinib—PLK3—female reproductive system—vaginal cancer	0.0057	0.00849	CbGeAlD
Ruxolitinib—DAPK2—uterine cervix—vaginal cancer	0.00557	0.00829	CbGeAlD
Ruxolitinib—CAMK2G—Cytokine Signaling in Immune system—EIF4A3—vaginal cancer	0.00551	0.0168	CbGpPWpGaD
Ruxolitinib—LTK—female reproductive system—vaginal cancer	0.0055	0.0082	CbGeAlD
Ruxolitinib—MAP3K3—Cytokine Signaling in Immune system—EIF4A3—vaginal cancer	0.00539	0.0164	CbGpPWpGaD
Ruxolitinib—JAK1—urethra—vaginal cancer	0.00536	0.00799	CbGeAlD
Ruxolitinib—DCLK1—urethra—vaginal cancer	0.00536	0.00799	CbGeAlD
Ruxolitinib—CAMK1—female reproductive system—vaginal cancer	0.00533	0.00794	CbGeAlD
Ruxolitinib—JAK1—endometrium—vaginal cancer	0.00528	0.00786	CbGeAlD
Ruxolitinib—JAK1—Interferon alpha/beta signaling—IFNA1—vaginal cancer	0.00526	0.016	CbGpPWpGaD
Ruxolitinib—CAMK1D—urethra—vaginal cancer	0.00523	0.0078	CbGeAlD
Ruxolitinib—PLK3—female gonad—vaginal cancer	0.00518	0.00772	CbGeAlD
Ruxolitinib—CLK2—uterine cervix—vaginal cancer	0.00518	0.00772	CbGeAlD
Ruxolitinib—MARK2—female reproductive system—vaginal cancer	0.00517	0.00771	CbGeAlD
Ruxolitinib—PLK3—vagina—vaginal cancer	0.00515	0.00768	CbGeAlD
Ruxolitinib—DAPK2—urethra—vaginal cancer	0.00511	0.00762	CbGeAlD
Ruxolitinib—JAK1—mammalian vulva—vaginal cancer	0.0051	0.00761	CbGeAlD
Ruxolitinib—DCLK1—mammalian vulva—vaginal cancer	0.0051	0.00761	CbGeAlD
Ruxolitinib—JAK3—Cytokine Signaling in Immune system—EIF4A3—vaginal cancer	0.00508	0.0155	CbGpPWpGaD
Ruxolitinib—ROCK1—epithelium—vaginal cancer	0.00507	0.00755	CbGeAlD
Ruxolitinib—DAPK2—endometrium—vaginal cancer	0.00503	0.0075	CbGeAlD
Ruxolitinib—CAMK1D—mammalian vulva—vaginal cancer	0.00498	0.00742	CbGeAlD
Ruxolitinib—JAK3—Interleukin receptor SHC signaling—IL2—vaginal cancer	0.00496	0.0151	CbGpPWpGaD
Ruxolitinib—DAPK2—mammalian vulva—vaginal cancer	0.00487	0.00726	CbGeAlD
Ruxolitinib—DCLK1—uterus—vaginal cancer	0.00486	0.00724	CbGeAlD
Ruxolitinib—JAK1—uterus—vaginal cancer	0.00486	0.00724	CbGeAlD
Ruxolitinib—CAMK1—female gonad—vaginal cancer	0.00485	0.00722	CbGeAlD
Ruxolitinib—TYK2—Interferon Signaling—EIF4A3—vaginal cancer	0.00483	0.0147	CbGpPWpGaD
Ruxolitinib—CAMK1—vagina—vaginal cancer	0.00482	0.00718	CbGeAlD
Ruxolitinib—DAPK3—urethra—vaginal cancer	0.00481	0.00717	CbGeAlD
Ruxolitinib—CLK2—urethra—vaginal cancer	0.00476	0.0071	CbGeAlD
Ruxolitinib—DAPK3—endometrium—vaginal cancer	0.00473	0.00705	CbGeAlD
Ruxolitinib—JAK3—IL2 signaling events mediated by STAT5—IL2—vaginal cancer	0.00469	0.0143	CbGpPWpGaD
Ruxolitinib—CLK2—endometrium—vaginal cancer	0.00469	0.00699	CbGeAlD
Ruxolitinib—NUAK2—uterine cervix—vaginal cancer	0.00466	0.00695	CbGeAlD
Ruxolitinib—LRRK2—Allograft Rejection—IL2—vaginal cancer	0.00464	0.0141	CbGpPWpGaD
Ruxolitinib—DAPK3—mammalian vulva—vaginal cancer	0.00458	0.00682	CbGeAlD
Ruxolitinib—CLK2—mammalian vulva—vaginal cancer	0.00454	0.00676	CbGeAlD
Ruxolitinib—JAK1—IL27-mediated signaling events—IL2—vaginal cancer	0.00452	0.0138	CbGpPWpGaD
Ruxolitinib—BMPR2—urethra—vaginal cancer	0.00449	0.00668	CbGeAlD
Ruxolitinib—JAK3—female reproductive system—vaginal cancer	0.0044	0.00655	CbGeAlD
Ruxolitinib—JAK1—female reproductive system—vaginal cancer	0.00437	0.00651	CbGeAlD
Ruxolitinib—JAK1—Cytokine Signaling in Immune system—EIF4A3—vaginal cancer	0.00437	0.0133	CbGpPWpGaD
Ruxolitinib—CAMK2G—uterine cervix—vaginal cancer	0.00437	0.00651	CbGeAlD
Ruxolitinib—BMP2K—uterine cervix—vaginal cancer	0.00437	0.00651	CbGeAlD
Ruxolitinib—DAPK3—uterus—vaginal cancer	0.00436	0.0065	CbGeAlD
Ruxolitinib—TAOK2—female gonad—vaginal cancer	0.00436	0.00649	CbGeAlD
Ruxolitinib—PLK4—female reproductive system—vaginal cancer	0.00434	0.00647	CbGeAlD
Ruxolitinib—TAOK2—vagina—vaginal cancer	0.00433	0.00645	CbGeAlD
Ruxolitinib—LRRK2—uterine cervix—vaginal cancer	0.00433	0.00645	CbGeAlD
Ruxolitinib—PLK1—Regulation of toll-like receptor signaling pathway—IFNA1—vaginal cancer	0.00433	0.0132	CbGpPWpGaD
Ruxolitinib—JAK1—Interleukin receptor SHC signaling—IL2—vaginal cancer	0.00426	0.013	CbGpPWpGaD
Ruxolitinib—PHKG2—female reproductive system—vaginal cancer	0.00424	0.00632	CbGeAlD
Ruxolitinib—NUAK2—endometrium—vaginal cancer	0.00422	0.00629	CbGeAlD
Ruxolitinib—STK16—female reproductive system—vaginal cancer	0.0041	0.00611	CbGeAlD
Ruxolitinib—HIPK2—female reproductive system—vaginal cancer	0.00408	0.00608	CbGeAlD
Ruxolitinib—NUAK2—mammalian vulva—vaginal cancer	0.00408	0.00608	CbGeAlD
Ruxolitinib—BMPR2—uterus—vaginal cancer	0.00407	0.00606	CbGeAlD
Ruxolitinib—JAK1—IL2 signaling events mediated by STAT5—IL2—vaginal cancer	0.00404	0.0123	CbGpPWpGaD
Ruxolitinib—CAMK2G—urethra—vaginal cancer	0.00401	0.00598	CbGeAlD
Ruxolitinib—JAK3—female gonad—vaginal cancer	0.004	0.00596	CbGeAlD
Ruxolitinib—MAP3K19—female reproductive system—vaginal cancer	0.004	0.00596	CbGeAlD
Ruxolitinib—LRRK2—urethra—vaginal cancer	0.00398	0.00593	CbGeAlD
Ruxolitinib—JAK1—female gonad—vaginal cancer	0.00398	0.00593	CbGeAlD
Ruxolitinib—JAK3—IL2 signaling events mediated by PI3K—IL2—vaginal cancer	0.00397	0.0121	CbGpPWpGaD
Ruxolitinib—MAP3K2—uterine cervix—vaginal cancer	0.00397	0.00591	CbGeAlD
Ruxolitinib—JAK1—vagina—vaginal cancer	0.00395	0.00589	CbGeAlD
Ruxolitinib—DCLK1—vagina—vaginal cancer	0.00395	0.00589	CbGeAlD
Ruxolitinib—CAMK2G—endometrium—vaginal cancer	0.00395	0.00589	CbGeAlD
Ruxolitinib—BMP2K—endometrium—vaginal cancer	0.00395	0.00589	CbGeAlD
Ruxolitinib—MAP3K7—uterine cervix—vaginal cancer	0.00393	0.00585	CbGeAlD
Ruxolitinib—DAPK3—female reproductive system—vaginal cancer	0.00392	0.00584	CbGeAlD
Ruxolitinib—LRRK2—endometrium—vaginal cancer	0.00391	0.00583	CbGeAlD
Ruxolitinib—CLK2—female reproductive system—vaginal cancer	0.00388	0.00579	CbGeAlD
Ruxolitinib—CAMK1D—female gonad—vaginal cancer	0.00388	0.00578	CbGeAlD
Ruxolitinib—TYK2—Interferon alpha/beta signaling—IFNA1—vaginal cancer	0.00388	0.0118	CbGpPWpGaD
Ruxolitinib—PHKG2—female gonad—vaginal cancer	0.00386	0.00575	CbGeAlD
Ruxolitinib—CAMK1D—vagina—vaginal cancer	0.00386	0.00575	CbGeAlD
Ruxolitinib—TYK2—uterine cervix—vaginal cancer	0.00386	0.00575	CbGeAlD
Ruxolitinib—MKNK2—epithelium—vaginal cancer	0.00384	0.00572	CbGeAlD
Ruxolitinib—IRAK1—uterine cervix—vaginal cancer	0.00381	0.00567	CbGeAlD
Ruxolitinib—MKNK2—uterine cervix—vaginal cancer	0.00381	0.00567	CbGeAlD
Ruxolitinib—DAPK2—female gonad—vaginal cancer	0.00379	0.00565	CbGeAlD
Ruxolitinib—LRRK2—mammalian vulva—vaginal cancer	0.00379	0.00564	CbGeAlD
Ruxolitinib—DAPK2—vagina—vaginal cancer	0.00377	0.00562	CbGeAlD
Ruxolitinib—ROCK1—female reproductive system—vaginal cancer	0.00376	0.00561	CbGeAlD
Ruxolitinib—RET—epithelium—vaginal cancer	0.00375	0.00558	CbGeAlD
Ruxolitinib—STK16—female gonad—vaginal cancer	0.00373	0.00556	CbGeAlD
Ruxolitinib—HIPK2—female gonad—vaginal cancer	0.00371	0.00553	CbGeAlD
Ruxolitinib—STK16—vagina—vaginal cancer	0.00371	0.00553	CbGeAlD
Ruxolitinib—DYRK1A—female reproductive system—vaginal cancer	0.00367	0.00547	CbGeAlD
Ruxolitinib—JAK2—Interferon Signaling—EIF4A3—vaginal cancer	0.00366	0.0111	CbGpPWpGaD
Ruxolitinib—BMPR2—female reproductive system—vaginal cancer	0.00366	0.00545	CbGeAlD
Ruxolitinib—CAMK2G—uterus—vaginal cancer	0.00364	0.00542	CbGeAlD
Ruxolitinib—MAP3K7—urethra—vaginal cancer	0.00361	0.00538	CbGeAlD
Ruxolitinib—JAK3—IL-2 Signaling Pathway—IL2—vaginal cancer	0.00358	0.0109	CbGpPWpGaD
Ruxolitinib—DAPK3—female gonad—vaginal cancer	0.00357	0.00532	CbGeAlD
Ruxolitinib—MAP3K7—endometrium—vaginal cancer	0.00355	0.00529	CbGeAlD
Ruxolitinib—DAPK3—vagina—vaginal cancer	0.00355	0.00528	CbGeAlD
Ruxolitinib—TYK2—urethra—vaginal cancer	0.00355	0.00528	CbGeAlD
Ruxolitinib—HIPK2—Gene Expression—EIF4A3—vaginal cancer	0.00354	0.0108	CbGpPWpGaD
Ruxolitinib—JAK2—epithelium—vaginal cancer	0.00354	0.00527	CbGeAlD
Ruxolitinib—CLK2—female gonad—vaginal cancer	0.00353	0.00527	CbGeAlD
Ruxolitinib—CLK2—vagina—vaginal cancer	0.00351	0.00523	CbGeAlD
Ruxolitinib—JAK2—uterine cervix—vaginal cancer	0.00351	0.00523	CbGeAlD
Ruxolitinib—MKNK2—urethra—vaginal cancer	0.0035	0.00521	CbGeAlD
Ruxolitinib—TYK2—endometrium—vaginal cancer	0.00349	0.0052	CbGeAlD
Ruxolitinib—PRKCE—IL2-mediated signaling events—IL2—vaginal cancer	0.00347	0.0106	CbGpPWpGaD
Ruxolitinib—JAK3—Interleukin-3, 5 and GM-CSF signaling—IL2—vaginal cancer	0.00345	0.0105	CbGpPWpGaD
Ruxolitinib—MKNK2—endometrium—vaginal cancer	0.00344	0.00513	CbGeAlD
Ruxolitinib—MAP3K7—mammalian vulva—vaginal cancer	0.00344	0.00512	CbGeAlD
Ruxolitinib—ROCK1—female gonad—vaginal cancer	0.00343	0.0051	CbGeAlD
Ruxolitinib—JAK1—IL2 signaling events mediated by PI3K—IL2—vaginal cancer	0.00341	0.0104	CbGpPWpGaD
Ruxolitinib—MAP3K3—uterine cervix—vaginal cancer	0.00338	0.00504	CbGeAlD
Ruxolitinib—TYK2—mammalian vulva—vaginal cancer	0.00338	0.00503	CbGeAlD
Ruxolitinib—DYRK1A—female gonad—vaginal cancer	0.00334	0.00498	CbGeAlD
Ruxolitinib—TYK2—IL27-mediated signaling events—IL2—vaginal cancer	0.00334	0.0102	CbGpPWpGaD
Ruxolitinib—MKNK2—mammalian vulva—vaginal cancer	0.00333	0.00496	CbGeAlD
Ruxolitinib—IRAK1—mammalian vulva—vaginal cancer	0.00333	0.00496	CbGeAlD
Ruxolitinib—BMPR2—female gonad—vaginal cancer	0.00333	0.00496	CbGeAlD
Ruxolitinib—IRAK1—Cytokine Signaling in Immune system—EIF4A3—vaginal cancer	0.00332	0.0101	CbGpPWpGaD
Ruxolitinib—BMPR2—vagina—vaginal cancer	0.00331	0.00493	CbGeAlD
Ruxolitinib—MAP3K2—uterus—vaginal cancer	0.00331	0.00492	CbGeAlD
Ruxolitinib—JAK3—Interleukin-2 signaling—IL2—vaginal cancer	0.00328	0.00996	CbGpPWpGaD
Ruxolitinib—MAP3K7—uterus—vaginal cancer	0.00327	0.00488	CbGeAlD
Ruxolitinib—BMP2K—female reproductive system—vaginal cancer	0.00327	0.00488	CbGeAlD
Ruxolitinib—CAMK2G—female reproductive system—vaginal cancer	0.00327	0.00488	CbGeAlD
Ruxolitinib—LRRK2—female reproductive system—vaginal cancer	0.00324	0.00483	CbGeAlD
Ruxolitinib—TYK2—Cytokine Signaling in Immune system—EIF4A3—vaginal cancer	0.00323	0.00981	CbGpPWpGaD
Ruxolitinib—JAK2—urethra—vaginal cancer	0.00323	0.00481	CbGeAlD
Ruxolitinib—JAK3—G beta:gamma signalling through PI3Kgamma—IL2—vaginal cancer	0.00322	0.00979	CbGpPWpGaD
Ruxolitinib—TYK2—uterus—vaginal cancer	0.00322	0.00479	CbGeAlD
Ruxolitinib—JAK1—IL-5 Signaling Pathway—IL2—vaginal cancer	0.00321	0.00975	CbGpPWpGaD
Ruxolitinib—NUAK2—female gonad—vaginal cancer	0.00318	0.00474	CbGeAlD
Ruxolitinib—JAK2—endometrium—vaginal cancer	0.00317	0.00473	CbGeAlD
Ruxolitinib—MKNK2—uterus—vaginal cancer	0.00317	0.00473	CbGeAlD
Ruxolitinib—JAK3—GPVI-mediated activation cascade—IL2—vaginal cancer	0.00317	0.00963	CbGpPWpGaD
Ruxolitinib—NUAK2—vagina—vaginal cancer	0.00316	0.00471	CbGeAlD
Ruxolitinib—MAP3K7—Cytokine Signaling in Immune system—EIF4A3—vaginal cancer	0.00313	0.00952	CbGpPWpGaD
Ruxolitinib—MAP3K3—urethra—vaginal cancer	0.00311	0.00463	CbGeAlD
Ruxolitinib—CAMK2G—Interferon Signaling—IFNA1—vaginal cancer	0.00309	0.00939	CbGpPWpGaD
Ruxolitinib—TAOK3—uterine cervix—vaginal cancer	0.00308	0.0046	CbGeAlD
Ruxolitinib—JAK1—IL-2 Signaling Pathway—IL2—vaginal cancer	0.00308	0.00938	CbGpPWpGaD
Ruxolitinib—JAK2—mammalian vulva—vaginal cancer	0.00307	0.00458	CbGeAlD
Ruxolitinib—JAK3—G-protein beta:gamma signalling—IL2—vaginal cancer	0.00307	0.00933	CbGpPWpGaD
Ruxolitinib—MAP3K3—endometrium—vaginal cancer	0.00306	0.00456	CbGeAlD
Ruxolitinib—BMP2K—female gonad—vaginal cancer	0.00298	0.00444	CbGeAlD
Ruxolitinib—CAMK2G—female gonad—vaginal cancer	0.00298	0.00444	CbGeAlD
Ruxolitinib—MAP3K2—female reproductive system—vaginal cancer	0.00297	0.00443	CbGeAlD
Ruxolitinib—JAK1—Interleukin-3, 5 and GM-CSF signaling—IL2—vaginal cancer	0.00297	0.00903	CbGpPWpGaD
Ruxolitinib—MAP3K3—mammalian vulva—vaginal cancer	0.00296	0.00441	CbGeAlD
Ruxolitinib—CAMK2G—vagina—vaginal cancer	0.00296	0.00441	CbGeAlD
Ruxolitinib—BMP2K—vagina—vaginal cancer	0.00296	0.00441	CbGeAlD
Ruxolitinib—PRKCE—Downstream signaling in naïve CD8+ T cells—IL2—vaginal cancer	0.00296	0.00899	CbGpPWpGaD
Ruxolitinib—LRRK2—female gonad—vaginal cancer	0.00295	0.0044	CbGeAlD
Ruxolitinib—LRRK2—vagina—vaginal cancer	0.00293	0.00437	CbGeAlD
Ruxolitinib—JAK3—IL2-mediated signaling events—IL2—vaginal cancer	0.00293	0.00891	CbGpPWpGaD
Ruxolitinib—TYK2—female reproductive system—vaginal cancer	0.00289	0.00431	CbGeAlD
Ruxolitinib—IRAK1—female reproductive system—vaginal cancer	0.00285	0.00425	CbGeAlD
Ruxolitinib—MKNK2—female reproductive system—vaginal cancer	0.00285	0.00425	CbGeAlD
Ruxolitinib—TAOK3—urethra—vaginal cancer	0.00283	0.00422	CbGeAlD
Ruxolitinib—JAK1—Interleukin-2 signaling—IL2—vaginal cancer	0.00282	0.00857	CbGpPWpGaD
Ruxolitinib—TAOK3—endometrium—vaginal cancer	0.00279	0.00416	CbGeAlD
Ruxolitinib—IRAK1—Toll-like Receptor Signaling Pathway—IFNA1—vaginal cancer	0.00279	0.00848	CbGpPWpGaD
Ruxolitinib—JAK1—G beta:gamma signalling through PI3Kgamma—IL2—vaginal cancer	0.00277	0.00843	CbGpPWpGaD
Ruxolitinib—JAK3—SHP2 signaling—IL2—vaginal cancer	0.00277	0.00842	CbGpPWpGaD
Ruxolitinib—JAK1—GPVI-mediated activation cascade—IL2—vaginal cancer	0.00273	0.00829	CbGpPWpGaD
Ruxolitinib—MAP3K2—female gonad—vaginal cancer	0.0027	0.00403	CbGeAlD
Ruxolitinib—TAOK3—mammalian vulva—vaginal cancer	0.0027	0.00402	CbGeAlD
Ruxolitinib—MAP3K7—female gonad—vaginal cancer	0.00268	0.00399	CbGeAlD
Ruxolitinib—MAP3K7—vagina—vaginal cancer	0.00266	0.00397	CbGeAlD
Ruxolitinib—JAK1—G-protein beta:gamma signalling—IL2—vaginal cancer	0.00264	0.00803	CbGpPWpGaD
Ruxolitinib—TYK2—female gonad—vaginal cancer	0.00263	0.00392	CbGeAlD
Ruxolitinib—JAK2—female reproductive system—vaginal cancer	0.00263	0.00392	CbGeAlD
Ruxolitinib—MAP3K7—Toll-like Receptor Signaling Pathway—IFNA1—vaginal cancer	0.00262	0.00798	CbGpPWpGaD
Ruxolitinib—TYK2—vagina—vaginal cancer	0.00261	0.0039	CbGeAlD
Ruxolitinib—MKNK2—female gonad—vaginal cancer	0.0026	0.00387	CbGeAlD
Ruxolitinib—IRAK1—female gonad—vaginal cancer	0.0026	0.00387	CbGeAlD
Ruxolitinib—MKNK2—vagina—vaginal cancer	0.00258	0.00384	CbGeAlD
Ruxolitinib—TAOK3—uterus—vaginal cancer	0.00257	0.00383	CbGeAlD
Ruxolitinib—PRKG2—Hemostasis—IFNA1—vaginal cancer	0.00254	0.00772	CbGpPWpGaD
Ruxolitinib—MAP3K3—female reproductive system—vaginal cancer	0.00253	0.00378	CbGeAlD
Ruxolitinib—JAK2—IL27-mediated signaling events—IL2—vaginal cancer	0.00253	0.0077	CbGpPWpGaD
Ruxolitinib—JAK1—IL2-mediated signaling events—IL2—vaginal cancer	0.00252	0.00767	CbGpPWpGaD
Ruxolitinib—TYK2—IL23-mediated signaling events—IL2—vaginal cancer	0.00252	0.00766	CbGpPWpGaD
Ruxolitinib—JAK1—Interferon Signaling—IFNA1—vaginal cancer	0.00245	0.00744	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—EIF4A3—vaginal cancer	0.00245	0.00744	CbGpPWpGaD
Ruxolitinib—JAK2—female gonad—vaginal cancer	0.00239	0.00357	CbGeAlD
Ruxolitinib—JAK2—Interleukin receptor SHC signaling—IL2—vaginal cancer	0.00239	0.00725	CbGpPWpGaD
Ruxolitinib—JAK1—SHP2 signaling—IL2—vaginal cancer	0.00238	0.00724	CbGpPWpGaD
Ruxolitinib—JAK2—vagina—vaginal cancer	0.00238	0.00354	CbGeAlD
Ruxolitinib—TAOK3—female reproductive system—vaginal cancer	0.00231	0.00344	CbGeAlD
Ruxolitinib—MAP3K3—female gonad—vaginal cancer	0.00231	0.00344	CbGeAlD
Ruxolitinib—MAP3K3—vagina—vaginal cancer	0.00229	0.00342	CbGeAlD
Ruxolitinib—IRAK1—Regulation of toll-like receptor signaling pathway—IFNA1—vaginal cancer	0.00218	0.00662	CbGpPWpGaD
Ruxolitinib—TAOK3—female gonad—vaginal cancer	0.0021	0.00313	CbGeAlD
Ruxolitinib—TAOK3—vagina—vaginal cancer	0.00209	0.00311	CbGeAlD
Ruxolitinib—TYK2—Interleukin-2 signaling—IL2—vaginal cancer	0.00208	0.00633	CbGpPWpGaD
Ruxolitinib—CAMK2G—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.00206	0.00627	CbGpPWpGaD
Ruxolitinib—MAP3K7—Regulation of toll-like receptor signaling pathway—IFNA1—vaginal cancer	0.00205	0.00623	CbGpPWpGaD
Ruxolitinib—MAP3K3—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.00201	0.00612	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—EIF4A3—vaginal cancer	0.00197	0.00598	CbGpPWpGaD
Ruxolitinib—JAK2—IL23-mediated signaling events—IL2—vaginal cancer	0.00191	0.0058	CbGpPWpGaD
Ruxolitinib—JAK3—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.0019	0.00578	CbGpPWpGaD
Ruxolitinib—TYK2—Interferon Signaling—IFNA1—vaginal cancer	0.00181	0.00549	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—EIF4A3—vaginal cancer	0.0018	0.00548	CbGpPWpGaD
Ruxolitinib—JAK2—IL-5 Signaling Pathway—IL2—vaginal cancer	0.00179	0.00545	CbGpPWpGaD
Ruxolitinib—MAP3K3—Signaling by Interleukins—IL2—vaginal cancer	0.00178	0.00543	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—EIF4A3—vaginal cancer	0.00176	0.00535	CbGpPWpGaD
Ruxolitinib—TYK2—IL12-mediated signaling events—IL2—vaginal cancer	0.00171	0.0052	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by Interleukins—IL2—vaginal cancer	0.00168	0.00512	CbGpPWpGaD
Ruxolitinib—JAK2—Interleukin-3, 5 and GM-CSF signaling—IL2—vaginal cancer	0.00166	0.00505	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—EIF4A3—vaginal cancer	0.00166	0.00505	CbGpPWpGaD
Ruxolitinib—JAK1—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.00163	0.00497	CbGpPWpGaD
Ruxolitinib—JAK2—Factors involved in megakaryocyte development and platelet production—IFNA1—vaginal cancer	0.00163	0.00495	CbGpPWpGaD
Ruxolitinib—JAK2—Interleukin-2 signaling—IL2—vaginal cancer	0.00158	0.00479	CbGpPWpGaD
Ruxolitinib—JAK2—G beta:gamma signalling through PI3Kgamma—IL2—vaginal cancer	0.00155	0.00471	CbGpPWpGaD
Ruxolitinib—JAK2—GPVI-mediated activation cascade—IL2—vaginal cancer	0.00152	0.00464	CbGpPWpGaD
Ruxolitinib—JAK2—G-protein beta:gamma signalling—IL2—vaginal cancer	0.00148	0.00449	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by Interleukins—IL2—vaginal cancer	0.00145	0.0044	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—EIF4A3—vaginal cancer	0.00143	0.00434	CbGpPWpGaD
Ruxolitinib—PRKCE—Hemostasis—IFNA1—vaginal cancer	0.0014	0.00426	CbGpPWpGaD
Ruxolitinib—JAK2—Interferon Signaling—IFNA1—vaginal cancer	0.00137	0.00416	CbGpPWpGaD
Ruxolitinib—JAK2—SHP2 signaling—IL2—vaginal cancer	0.00133	0.00405	CbGpPWpGaD
Ruxolitinib—JAK2—IL12-mediated signaling events—IL2—vaginal cancer	0.0013	0.00394	CbGpPWpGaD
Ruxolitinib—PRKCE—Innate Immune System—IFNA1—vaginal cancer	0.00126	0.00384	CbGpPWpGaD
Ruxolitinib—IRAK1—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.00124	0.00378	CbGpPWpGaD
Ruxolitinib—TYK2—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.00121	0.00367	CbGpPWpGaD
Ruxolitinib—JAK3—Hemostasis—IFNA1—vaginal cancer	0.00118	0.0036	CbGpPWpGaD
Ruxolitinib—MAP3K7—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.00117	0.00356	CbGpPWpGaD
Ruxolitinib—PRKCE—Platelet activation, signaling and aggregation—IL2—vaginal cancer	0.00112	0.00342	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling by Interleukins—IL2—vaginal cancer	0.0011	0.00335	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—EIF4A3—vaginal cancer	0.00109	0.0033	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by Interleukins—IL2—vaginal cancer	0.00107	0.00325	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—EIF4A3—vaginal cancer	0.00105	0.00321	CbGpPWpGaD
Ruxolitinib—PRKG2—Hemostasis—IL2—vaginal cancer	0.00105	0.00319	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling by Interleukins—IL2—vaginal cancer	0.00104	0.00315	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—EIF4A3—vaginal cancer	0.00102	0.00311	CbGpPWpGaD
Ruxolitinib—JAK1—Hemostasis—IFNA1—vaginal cancer	0.00102	0.0031	CbGpPWpGaD
Ruxolitinib—JAK3—Platelet activation, signaling and aggregation—IL2—vaginal cancer	0.000949	0.00289	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—IFNA1—vaginal cancer	0.000916	0.00279	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.000914	0.00278	CbGpPWpGaD
Ruxolitinib—CAMK2G—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000853	0.00259	CbGpPWpGaD
Ruxolitinib—MAP3K3—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000833	0.00253	CbGpPWpGaD
Ruxolitinib—JAK1—Platelet activation, signaling and aggregation—IL2—vaginal cancer	0.000817	0.00248	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by Interleukins—IL2—vaginal cancer	0.00081	0.00246	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—EIF4A3—vaginal cancer	0.000799	0.00243	CbGpPWpGaD
Ruxolitinib—JAK3—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000786	0.00239	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—IFNA1—vaginal cancer	0.000735	0.00224	CbGpPWpGaD
Ruxolitinib—CYP3A4—female reproductive system—vaginal cancer	0.000702	0.00105	CbGeAlD
Ruxolitinib—IRAK1—Innate Immune System—IFNA1—vaginal cancer	0.000697	0.00212	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—IFNA1—vaginal cancer	0.000677	0.00206	CbGpPWpGaD
Ruxolitinib—JAK1—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000676	0.00206	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—IFNA1—vaginal cancer	0.000673	0.00205	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—IFNA1—vaginal cancer	0.000658	0.002	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—IFNA1—vaginal cancer	0.000656	0.002	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—IFNA1—vaginal cancer	0.00062	0.00189	CbGpPWpGaD
Ruxolitinib—PRKCE—Hemostasis—IL2—vaginal cancer	0.00058	0.00176	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—IFNA1—vaginal cancer	0.00057	0.00173	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—IFNA1—vaginal cancer	0.000534	0.00162	CbGpPWpGaD
Ruxolitinib—IRAK1—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000514	0.00156	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—IFNA1—vaginal cancer	0.000513	0.00156	CbGpPWpGaD
Ruxolitinib—TYK2—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000499	0.00152	CbGpPWpGaD
Ruxolitinib—JAK3—Hemostasis—IL2—vaginal cancer	0.000489	0.00149	CbGpPWpGaD
Ruxolitinib—MAP3K7—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000484	0.00147	CbGpPWpGaD
Ruxolitinib—JAK2—Platelet activation, signaling and aggregation—IL2—vaginal cancer	0.000457	0.00139	CbGpPWpGaD
Ruxolitinib—JAK1—Hemostasis—IL2—vaginal cancer	0.000421	0.00128	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IFNA1—vaginal cancer	0.000406	0.00123	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IFNA1—vaginal cancer	0.000394	0.0012	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IFNA1—vaginal cancer	0.000382	0.00116	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000378	0.00115	CbGpPWpGaD
Ruxolitinib—PRKCE—GPCR downstream signaling—IL2—vaginal cancer	0.000366	0.00111	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—IL2—vaginal cancer	0.000356	0.00108	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—IL2—vaginal cancer	0.000335	0.00102	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—IL2—vaginal cancer	0.000333	0.00101	CbGpPWpGaD
Ruxolitinib—JAK3—GPCR downstream signaling—IL2—vaginal cancer	0.000309	0.00094	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—IL2—vaginal cancer	0.000304	0.000925	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—IL2—vaginal cancer	0.000303	0.000921	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IFNA1—vaginal cancer	0.000299	0.000908	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—IL2—vaginal cancer	0.000281	0.000854	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—IL2—vaginal cancer	0.000278	0.000847	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—IL2—vaginal cancer	0.000272	0.000827	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—IL2—vaginal cancer	0.000266	0.000809	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—IL2—vaginal cancer	0.000262	0.000796	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—IL2—vaginal cancer	0.000257	0.00078	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—IL2—vaginal cancer	0.000242	0.000735	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—IL2—vaginal cancer	0.000238	0.000723	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—IL2—vaginal cancer	0.000236	0.000716	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—IL2—vaginal cancer	0.000221	0.000671	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—IL2—vaginal cancer	0.000197	0.000598	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—IL2—vaginal cancer	0.000178	0.000542	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL2—vaginal cancer	0.000168	0.00051	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IL2—vaginal cancer	0.000166	0.000504	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL2—vaginal cancer	0.000163	0.000496	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL2—vaginal cancer	0.000158	0.000481	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—IL2—vaginal cancer	0.000149	0.000453	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IL2—vaginal cancer	0.000143	0.000434	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IL2—vaginal cancer	0.00014	0.000427	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—IL2—vaginal cancer	0.000135	0.000411	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL2—vaginal cancer	0.000123	0.000376	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL2—vaginal cancer	0.000109	0.00033	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL2—vaginal cancer	0.000105	0.00032	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL2—vaginal cancer	0.000102	0.000311	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL2—vaginal cancer	7.98e-05	0.000243	CbGpPWpGaD
